Anavex Life Sciences Corp AVXL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVXL is a good fit for your portfolio.
News
-
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Anavex Life Sciences Corp. with Losses to Contact the Firm
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex
-
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit
-
DEADLINE ALERT for VTYX, IRBT, and AVXL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
-
Anavex Life Sciences Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 13, 2024 to Discuss Your Rights - AVXL
-
ANAVEX LIFE SCIENCES CORPORATION (NASDAQ: AVXL) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Anavex Life Sciences Corporation Investors of Upcoming Deadline
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Anavex Life Sciences Corp. - AVXL
Trading Information
- Previous Close Price
- $3.69
- Day Range
- $3.70–3.91
- 52-Week Range
- $3.60–10.44
- Bid/Ask
- $3.75 / $3.76
- Market Cap
- $308.74 Mil
- Volume/Avg
- 568,984 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 40
- Website
- https://www.anavex.com
Comparables
Valuation
|
Metric
|
AVXL
|
ACRS
|
RYTM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.30 | 0.55 | 13.66 |
Price/Sales | — | 2.73 | 29.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AVXL
|
ACRS
|
RYTM
|
|---|---|---|---|
Quick Ratio | 11.79 | 3.86 | 5.27 |
Current Ratio | 11.85 | 4.16 | 5.58 |
Interest Coverage | — | — | −13.26 |
Quick Ratio
AVXL
ACRS
RYTM
Profitability
|
Metric
|
AVXL
|
ACRS
|
RYTM
|
|---|---|---|---|
Return on Assets (Normalized) | −21.26% | −38.26% | −46.12% |
Return on Equity (Normalized) | −23.17% | −50.08% | −76.97% |
Return on Invested Capital (Normalized) | −27.24% | −49.93% | −76.40% |
Return on Assets
AVXL
ACRS
RYTM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Fsdlzfwbq | Xcr | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndczcdxv | Zbxmjrr | $103.3 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qmkqfnmsn | Tyntvxy | $98.8 Bil | |
MRNA
| Moderna Inc | Zcxkfscv | Yngj | $38.8 Bil | |
ARGX
| argenx SE ADR | Wsjhdss | Znj | $21.3 Bil | |
BNTX
| BioNTech SE ADR | Vmndnfvmx | Nzqcb | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Txdqpcnhx | Wtwgfk | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Sxhjkqt | Rsjly | $17.0 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lllvpkyhsb | Dgfmt | $12.4 Bil | |
INCY
| Incyte Corp | Nbhspvb | Wgqqb | $11.9 Bil |